Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA and EMA accept regulatory submissions for dacomitinib

April 5, 2018

Novel orally bioavailable rohitukine derivative shows promise in xenograft cancer models

April 5, 2018

Triple combination program for the treatment of cystic fibrosis receives FDA fast track designation

April 5, 2018

Immunic initiates phase III CALDOSE-1 study of IMU-838

April 5, 2018

Phase III study evaluates ASTX-727 versus intravenous decitabine in patients with MDS and CMML

April 5, 2018

Corvus Pharmaceuticals initiates phase I study of CPI-006 in patients with advanced solid tumors

April 5, 2018

Nkx-6.1 identified as diagnostic marker of lung and pancreatic NETs

April 4, 2018

Sellas reports interim phase IIb data on Herceptin + NeuVax in breast cancer

April 4, 2018

SOX-9 unveiled as potential prognostic marker in lymphoma

April 4, 2018

Pfizer and Allogene enter asset contribution agreement for Pfizer's CAR T portfolio

April 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...